Xencor, Inc. (NASDAQ:XNCR) Shares Bought by Arizona State Retirement System

Arizona State Retirement System raised its position in Xencor, Inc. (NASDAQ:XNCR) by 13.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,190 shares of the biopharmaceutical company’s stock after acquiring an additional 2,132 shares during the period. Arizona State Retirement System’s holdings in Xencor were worth $418,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. KBC Group NV lifted its stake in shares of Xencor by 63.5% during the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 1,213 shares during the period. Thrivent Financial for Lutherans lifted its stake in shares of Xencor by 127.3% during the third quarter. Thrivent Financial for Lutherans now owns 116,369 shares of the biopharmaceutical company’s stock worth $2,340,000 after buying an additional 65,180 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Xencor during the third quarter worth $362,000. Intech Investment Management LLC acquired a new stake in shares of Xencor during the third quarter worth $368,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Xencor by 7.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company’s stock worth $12,609,000 after buying an additional 40,788 shares during the period.

Analysts Set New Price Targets

XNCR has been the subject of several research reports. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday. Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.38.

Xencor Stock Down 0.9 %

XNCR opened at $12.76 on Friday. Xencor, Inc. has a fifty-two week low of $12.69 and a fifty-two week high of $27.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a fifty day moving average of $17.36 and a two-hundred day moving average of $20.44. The stock has a market capitalization of $899.10 million, a price-to-earnings ratio of -3.99 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million during the quarter, compared to analysts’ expectations of $17.14 million. On average, research analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.